Differential effector engagement by oncogenic KRAS

Yuan, Tina L., Amzallag, Arnaud, Bagni, Rachel, Yi, Ming, Afghani, Shervin, Burgan, William, Fer, Nicole, Strathern, Leslie A. +22 more·2018·Cell Reports
DOI 10.1016/j.celrep.2018.01.051

Cited by (151)

Items 101–151 of 151

  1. STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer
    Stephen D’Amico, Varvara Kirillov, Oleksi Petrenko, Nancy C. Reich · 2024 · eLife
  2. A signalling cascade for Ral
    You Wu, David J. Reiner · 2021 · Small GTPases
  3. Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer
    Hong‐Shuai Li, Chengming Liu, Yan Wang · 2022 · Future Oncology
  4. Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer
    Derek K. Cheng, Tobiloba E. Oni, Youngkyu Park, Jennifer S. Thalappillil, Hsiu-Chi Ting, Brinda Alagesan, Nadia V. Prasad, Keith D. Rivera, Darryl Pappin, Linda Van Aelst et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  5. Exploring the role of monocarboxylate transporter 4 in diverse KRAS mutation subtypes of colorectal Cancer
    Qian Gong, Jing Huang, Qingshu Li, Shuxian Zhang, Ming Xiao, Ming Li, Yaying Yang, Yi Ping Tang, Yalan Wang · 2025 · Scientific Reports
  6. FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer
    Suzan Ber, Ming Hui Yang, Marco Sciacovelli, Shamith Samarajiwa, Khushali Patel, Efterpi Nikitopoulou, Annie Howitt, Simon J. Cook, Ashok R. Venkitaraman, Christian Frezza et al. · 2025 · EMBO Reports
  7. Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer
    Linsha Zhu, Xiangbo Jia, Lei Xu, Li Chen, Xiangning Fu, Hua Yan, Bo Ai, Shu Peng · 2025 · iScience
  8. Parallel Rap1>RalGEF>Ral and Ras signals sculpt the C. elegans nervous system
    Jacob I. Mardick, Neal R. Rasmussen, Bruce Wightman, David J. Reiner · 2021 · Developmental Biology
  9. Development of an invasion score based on metastasis-related pathway activity profiles for identifying invasive molecular subtypes of lung adenocarcinoma
    Tao Han, Yafeng Liu, Jiawei Zhou, Jianqiang Guo, Yingru Xing, Jun Xie, Ying Bai, Jing Wu, Dong Hu · 2024 · Scientific Reports
  10. Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells
    Masahide Osaki, Seitaro Terakura, Shiho Hirano, Takuma Iwasa, Kanako C. Hatanaka, Yutaka Hatanaka, Masaki Sunagawa, Toshio Kokuryo, Yoshitaka Adachi, Yuki Takeuchi et al. · 2025 · Journal for ImmunoTherapy of Cancer
  11. STAT3 sustains tumorigenicity following mutant KRAS ablation
    Stephen D’Amico, Varvara Kirillov, Jingxuan Liu, Zhijuan Qiu, Xinyuan Lei, Hong Qin, Brian S. Sheridan, Nancy C. Reich · 2025 · EMBO Reports
  12. STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer
    Stephen D’Amico, Varvara Kirillov, Oleksi Petrenko, Nancy C. Reich · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  13. TIMP-1 Modulation Correlates with KRAS Dependency and EMT Induction in NSCLC
    Ilamathi M-Thirusenthilarasan, Pankaj Kumar Ahluwalia, Nithyananda Thorenoor, Sampa Ghoshal-Gupta, Byung Rho Lee, Bilal Karim Siddiqui, Ravindra B Kolhe, Amyn M. Rojiani, Mumtaz V. Rojiani · 2025 · Cells
  14. RAS mutations and colorectal cancer metabolism: a metabolomic analysis of tissue samples
    Jianjiong Li, Buyuan Dong · 2025 · BMC Cancer
  15. Understanding the performance of HIV-1 viral vector vaccines: adenovirus and poxvirus case studies
    Mahdiyeh M. Manafi, Touraj Aligholipour Farzani, Nallely Espinoza, Al Ozonoff, Pardis Christine Sabeti · 2026 · Frontiers in Immunology
  16. Identification of BIK as an unfavorable prognostic marker and novel therapeutic target in microsatellite stable colorectal cancer harboring KRAS mutations.
    Peng Liu, Feng Jiao, Zhenghua Zhang, Feilong Zhao, Jinping Cai, Shiqing Chen, Tao Fu, Min Li · 2022 · PubMed Central
  17. KRAS-mutated non-small cell lung cancer: new therapy strategies
    Константин Константинович Лактионов, К. А. Саранцева, Нелюбина Лидия Александровна, S. V. Gamayunov, Е. А. Kolesnikova, M. Gordiev · 2024 · Siberian Journal of Oncology
  18. Targeted phosphoproteomics of the Ras signaling network reveal regulatory mechanisms mediated by oncogenic KRAS
    Anatoly Urisman, Tina L. Yuan, Marena I. Trinidad, John H. Morris, Shervin Afghani, Juan A. Osés-Prieto, Cayde D. Ritchie, Muhammad Saddiq Zahari, Cyril H. Benes, Alma L. Burlingame et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  19. Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition
    Xiangyu Ge, Jaffarguriqbal Singh, Wenxue Li, Cassandra Santaella Bishop, Christian Felipe Ruiz, Moitrayee Bhattacharyya, Yansheng Liu, Mandar Deepak Muzumdar · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  20. Mapping Effector–Phenotype Landscapes in KRAS-Driven Cancers
    Peter S. Winter, Kris C. Wood · 2018 · Trends in cancer
  21. Examining the markers of vitamin C cytotoxicity in pancreatic ductal adenocarcinoma
    Cassia Warren · 2019 · cIRcle (University of British Columbia)
  22. Faculty Opinions recommendation of RAC1P29S induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance.
    Jonathan Chernoff · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  23. Faculty Opinions recommendation of RAC1P29S induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance.
    Paul Timpson, David Herrmann · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  24. Lung Cancer and KRAS -Its Molecular Biology/Genetics and Therapeutic Strategy-
    Takamasa Koga, Tetsuya Mitsudomi · 2022 · Haigan
  25. Evaluation of K-Ras4B dimer interfaces and the role of Raf effectors
    Alexios Chatzigoulas, Ioannis Andreadelis, Stefan Doerr, Christos Lamprakis, Anastasia Theodoropoulou, John I. Manchester, Camilo Velez‐Vega, José S. Duca, Zoe Cournia · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  26. Data from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
    Dandan Li, Anne M. Miermont, Rushikesh V. Sable, Humair S. Quadri, Lesley A. Mathews Griner, Scott E. Martin, Taivan Odzorig, Soumita De, Marc Ferrer, Astin S. Powers et al. · 2023
  27. Data from Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
    Natalia García, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman et al. · 2023
  28. Data from Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
    Natalia García, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman et al. · 2023
  29. Data from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
    Dandan Li, Anne M. Miermont, Rushikesh V. Sable, Humair S. Quadri, Lesley A. Mathews Griner, Scott E. Martin, Taivan Odzorig, Soumita De, Marc Ferrer, Astin S. Powers et al. · 2023
  30. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  31. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  32. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  33. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
    Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper, Neal S. Akhave, Teng Zhou, Lukas Delasos, James Kevin Hicks, Mihaela D. Aldea, Gabriele Minuti et al. · 2023
  34. Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma
    Yuchan Li · 2023
  35. STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer
    Stephen D’Amico, Varvara Kirillov, Oleksi Petrenko, Nancy C. Reich · 2024 · eLife
  36. KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation.
    Jonathan Chernoff, Konstantin Budagyan, Alexa Christine Cannon, Adam G. Chatoff, Nathaniel W. Snyder, Alison Kurimchak, James S. Duncan · 2024 · Research Square
  37. Recombinant strains of oncolytic vaccinia virus for cancer immunotherapy
    Yasmin Shakiba, Pavel O. Vorobyev, M. Mahmoud, A. Hamad, Д. В. Кочетков, Gaukhar M. Yusubalieva, Vladimir P. Baklaushev, Peter M. Chumakov, Anastasiya V. Lipatova · 2023 · Biochemistry (Moscow)
  38. Author Response: STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer
    Stephen D’Amico, Varvara Kirillov, Oleksi Petrenko, Nancy C. Reich · 2024 · eLife
  39. An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer
    Christiana Mo, Bhawneet Chadha, Chaoyuan Kuang · 2024 · Clinical Colorectal Cancer
  40. Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
    Fiona M. Healy, Amy L. Turner, Vanessa Marensi, David J. MacEwan · 2024 · Frontiers in Pharmacology
  41. Introduction to RAS biology
    Channing J. Der, Frank McCormick · 2024 · Elsevier eBooks
  42. KRAS G12 mutant alleles differentially control glutamine metabolism via FOXO1
    Suzan Ber, Ming Hui Yang, Marco Sciacovelli, Shamith Samarajiwa, Khushali Patel, Efterpi Nikitopoulou, Annie Howitt, Simon J. Cook, Ashok R. Venkitaraman, Christian Frezza et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  43. The Ral small GTPase is an essential regulator of exocyst complex function in secretion
    You Wu, David J. Reiner · 2026 · The Journal of Cell Biology
  44. Cooperativity between Ras pathway mutations in colonic tumorigenesis
    Christian William Johnson, Anna Idelevich, Bing Shui, Alison W. Tisdale, Eve O’Donoghue, Joshua Cook, Shannon Hull, Moon Hee Yang, Shikha Sheth, Elizabeth M. Terrell et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  45. Remodeling of KRAS interactome induced by clinically relevant RAS inhibitors reveals convergent responses and a KRAS-mediated regulation of directional cell migration
    Yang Yang, Charles Y. Cho, Ansgar Brock, Doug Quackenbush, Kaisheng Chen, Frederick Lo, Cyril H. Benes, Jacob R. Haling · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  46. STRUCTURE-BASED OPTIMIZATION OF ADAGRASIB (MRTX849) ANALOGUES: ADVANCED COMPUTATIONAL FRAMEWORK FOR KRAS G12D INHIBITOR DESIGN
    Ayşegül Varol · 2025 · Mugla Journal of Science and Technology
  47. Deciphering the metabolic bases of Drosophila intestinal tumors
    Pierre Delamotte · 2024 · theses.fr (ABES)
  48. Functional Interpretation of Differential Gene Expression in Cancer: From Lists to Mechanisms
    Amancio Carnero · 2026 · Gene Expression
  49. Chronic cigarette smoke exposure induces distinct stem cell states driving genetic driver–specific non–small cell lung cancer subtypes
    Na Wang, Raksha Padaki, Sara-Jayne Thursby, Ray-Whay Chiu Yen, Leslie Cope, Malcolm V. Brock, Edward W. Gabrielson, Hariharan Easwaran, Stephen B. Baylin, Michelle J. Vaz · 2026 · Proceedings of the National Academy of Sciences
  50. Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses
    Yang Yang, TingYu Liu, Charles Y. Cho, Xianzhong Liu, Ansgar Brock, Doug Quackenbush, Kaisheng Chen, Frederick Lo, Cyril H. Benes, Jacob R. Haling · 2026 · Oncogene
  51. BindingDB Entry 50016438: Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
    BindingDB · 2023 · UC San Diego